Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV‐associated cryptococcal meningitis‐infected patients
Open Access
- 1 March 2010
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 11 (4), 276-281
- https://doi.org/10.1111/j.1468-1293.2009.00778.x
Abstract
Objectives The aim of the present study was to assess fluconazole pharmacokinetic measures in serum and cerebrospinal fluid (CSF); and the correlation of these measures with clinical outcomes of invasive fungal infections. Methods A randomized trial was conducted in HIV‐infected patients receiving three different regimens of fluconazole plus amphotericin B (AmB) for the treatment of cryptococcal meningitis. Regimens included fluconazole 400 mg/day+AmB (AmB+Fluc400) or fluconazole 800 mg/day+AmB (AmB+Fluc800) (14 days followed by fluconazole alone at the randomized dose for 56 days); or AmB alone for 14 days followed by fluconazole 400 mg/day for 56 days. Serum (at 24 h after dosing) and CSF samples were taken at baseline and days 14 and 70 (serum only) for fluconazole measurement, using gas–liquid chromatography. Results Sixty‐four treated patients had fluconazole measurements: 11 in the AmB group, 12 in the AmB+Fluc400 group and 41 in the AmB+Fluc800 group. Day 14 serum concentration geometric means were 24.7 mg/L for AmB+Fluc400 and 37.0 mg/L for AmB+Fluc800. Correspondingly, CSF concentration geometric means were 25.1 mg/L and 32.7 mg/L. Day 14 Serum and CSF concentrations were highly correlated with AmB+Fluc800 (Pr=0.873) and AmB+Fluc400 (P=0.005, r=0.943). Increased serum area under the curve (AUC) appears to be associated with decreased mortality at day 70 (P=0.061, odds ratio=2.19) as well as with increased study composite endpoint success at days 42 and 70 (P=0.081, odds ratio=2.25 and 0.058, 2.89, respectively). Conclusion High fluconazole dosage (800 mg/day) for the treatment of HIV‐associated cryptococcal meningitis was associated with high serum and CSF fluconazole concentration. Overall, high serum and CSF concentration appear to be associated with increased survival and primary composite endpoint success.This publication has 13 references indexed in Scilit:
- A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV‐Associated Cryptococcal MeningitisClinical Infectious Diseases, 2009
- Update on Azole AntifungalsSeminars in Respiratory and Critical Care Medicine, 2008
- HIV-associated cryptococcal meningitisAIDS, 2007
- CNS pharmacokinetics of antifungal agentsExpert Opinion on Drug Metabolism & Toxicology, 2007
- Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility TestingClinical Microbiology Reviews, 2006
- Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic MycosesClinical Pharmacokinetics, 1997
- Fluconazole penetration in cerebral parenchyma in humans at steady stateAntimicrobial Agents and Chemotherapy, 1995
- Clinical Pharmacokinetics of FluconazoleClinical Pharmacokinetics, 1993
- Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal MeningitisThe New England Journal of Medicine, 1992
- Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detectionAntimicrobial Agents and Chemotherapy, 1989